Browsing Tag
American Academy of Neurology
3 posts
Is the gMG treatment race entering a lower-burden dosing phase?
Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis treatment, REGN stock sentiment and siRNA competition today!
How GTx-104 may improve ICU dosing consistency in subarachnoid hemorrhage
How Grace Therapeutics’ GTx-104 could improve ICU dosing consistency and reshape hospital economics in subarachnoid hemorrhage care. Read the full BNT analysis.
Could essential tremor finally be entering a new treatment era after Praxis’ Phase 3 results?
Praxis Precision Medicines’ Phase 3 results could reshape essential tremor treatment and re-rate the neurology market. Read what this means for investors.